Cargando…

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis

OBJECTIVE: Systematic Review was used to evaluate the efficacy and safety of Dalfampridine (DAP) in the treatment of Mobility Disability (MS) in patients with Multiple Sclerosis. METHODS: Clinical randomized controlled studies about DAP and placebo in the treatment of Mobility Disability in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Jianzhen, Wu, Xiaohui, Chen, Yanmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742383/ https://www.ncbi.nlm.nih.gov/pubmed/31513613 http://dx.doi.org/10.1371/journal.pone.0222288

Ejemplares similares

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial
por: Pozzilli, Carlo, et al.
Publicado: (2021)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study
por: Plummer, Prudence, et al.
Publicado: (2022)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
por: Guo, Amy, et al.
Publicado: (2016)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
por: Goodman, Andrew D, et al.
Publicado: (2015)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Mobility disability and the pattern of accelerometer-derived sedentary and physical activity behaviors in people with multiple sclerosis
por: Ezeugwu, Victor, et al.
Publicado: (2015)

Impairment, disability and fatigue in multiple sclerosis
por: Shahrbanian, Shahnaz, et al.
Publicado: (2018)

Long‐term evolution of multiple sclerosis disability in the treatment era
por: Cree, Bruce A. C., et al.
Publicado: (2016)

Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study
por: Tortorella, Paola, et al.
Publicado: (2014)

Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways
por: Caggiano, Anthony, et al.
Publicado: (2013)

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
por: Page, Stephen J., et al.
Publicado: (2020)

Factors Influencing the Degree of Disability in Patients With Multiple Sclerosis
por: Xue, Huiru, et al.
Publicado: (2021)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis
por: Moosazadeh, Mahmood, et al.
Publicado: (2021)

Integrated care for intellectual disability and multiple sclerosis
por: Jansen, Daniëlle
Publicado: (2006)

Predicting the profile of increasing disability in multiple sclerosis
por: Tomassini, Valentina, et al.
Publicado: (2018)

Determinants of disability development in patients with multiple sclerosis
por: Kara, Fatma, et al.
Publicado: (2021)

The role of disconnection in explaining disability in multiple sclerosis
por: Lapucci, Caterina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgapq2avphoodmqdo1vpt69cm3